• Jaguar Health Inc JAGX.OQ reported a quarterly adjusted loss of $16.70​​ per share for the quarter ended March 31, higher than the same quarter last year, when the company reported EPS of $-105.00. The lone analyst forecast for the quarter was for a loss of $18.00 per share.

• Revenue fell 5.8% to $2.21 million from a year ago; analysts expected $2.82 million.

• Jaguar Health Inc's reported EPS for the quarter was a loss of $16.70​.

• Jaguar Health Inc shares had risen by 15.5% this quarter and lost 78.2% so far this year.

FORECAST CHANGES

• The mean earnings estimate of analysts was unchanged in the last three months.​

• In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.

RECOMMENDATIONS

• The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 1 "strong buy" or "buy," no "hold" and no "sell" or "strong sell." The average consensus recommendation for the pharmaceuticals peer group is "buy."

• Wall Street's median 12-month price target for Jaguar Health Inc is $16.00

This summary was machine generated from LSEG data May 16 at 07:04 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)